Corcept Therapeutics Inc logo

CORT - Corcept Therapeutics Inc Share Price

$17.44 -0.3  -1.9%

Last Trade - 9:00pm

Mid Cap
Market Cap £1.59bn
Enterprise Value £1.27bn
Revenue £271.3m
Position in Universe 1834th / 6436
Unlock CORT Revenue
Relative Strength (%)
1m -5.37%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
26.6 50.3 81.3 159.2 251.2 306.5 366.2 361 +63.1%
+1,760 -54.3 +29.1 +11.7 -11.7
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Corcept Therapeutics Incorporated revenues increased 33% to $181.8M. Net income increased 52% to $58.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest and other income (expense), net increase of 9% to $2.5M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CORT
Graphical History


CORT Revenue Unlock CORT Revenue

Net Income

CORT Net Income Unlock CORT Revenue

Normalised EPS

CORT Normalised EPS Unlock CORT Revenue

PE Ratio Range

CORT PE Ratio Range Unlock CORT Revenue

Dividend Yield Range

CORT Dividend Yield Range Unlock CORT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CORT EPS Forecasts Unlock CORT Revenue
Profile Summary

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 13, 1998
Public Since April 15, 2004
No. of Shareholders: 27
No. of Employees: 206
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Capital Market
Shares in Issue 115,557,656
Free Float (0.0%)
Eligible for
CORT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CORT
Upcoming Events for CORT
Thursday 5th November, 2020 Estimate
Q3 2020 Corcept Therapeutics Inc Earnings Release
Thursday 18th February, 2021 Estimate
Q4 2020 Corcept Therapeutics Inc Earnings Release
Frequently Asked Questions for Corcept Therapeutics Inc
What is the Corcept Therapeutics Inc share price?

As of 9:00pm, shares in Corcept Therapeutics Inc are trading at $17.44, giving the company a market capitalisation of £1.59bn. This share price information is delayed by 15 minutes.

How has the Corcept Therapeutics Inc share price performed this year?

Shares in Corcept Therapeutics Inc are currently trading at $17.44 and the price has moved by 28.01% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Corcept Therapeutics Inc price has moved by 11.91% over the past year.

What are the analyst and broker recommendations for Corcept Therapeutics Inc?

Of the analysts with advisory recommendations for Corcept Therapeutics Inc, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Corcept Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Corcept Therapeutics Inc next release its financial results?

Corcept Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Corcept Therapeutics Inc dividend yield?

Corcept Therapeutics Inc does not currently pay a dividend.

Does Corcept Therapeutics Inc pay a dividend?

Corcept Therapeutics Inc does not currently pay a dividend.

When does Corcept Therapeutics Inc next pay dividends?

Corcept Therapeutics Inc does not currently pay a dividend.

How do I buy Corcept Therapeutics Inc shares?

To buy shares in Corcept Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Corcept Therapeutics Inc?

Shares in Corcept Therapeutics Inc are currently trading at $17.44, giving the company a market capitalisation of £1.59bn.

Where are Corcept Therapeutics Inc shares listed? Where are Corcept Therapeutics Inc shares listed?

Here are the trading details for Corcept Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CORT
What kind of share is Corcept Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Corcept Therapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Corcept Therapeutics Inc share price forecast 2020?

Shares in Corcept Therapeutics Inc are currently priced at $17.44. At that level they are trading at 0.17% premium to the analyst consensus target price of 0.00.

Analysts covering Corcept Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.858 for the next financial year.

How can I tell whether the Corcept Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Corcept Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 15.98%. At the current price of $17.44, shares in Corcept Therapeutics Inc are trading at 23.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Corcept Therapeutics Inc PE Ratio?

The Corcept Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 19.09. The shares are currently trading at $17.44.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Corcept Therapeutics Inc?

Corcept Therapeutics Inc's management team is headed by:

Joseph Belanoff - PRE
James Wilson - CHM
George Baker - IND
David Mahoney - IND
Gary Robb - CFO
Daniel Swisher - IND
Sean Maduck - SVP
Andreas Grauer - OTH
Kimberly Park - IND
Gregg Alton - IND
J.D. Lyon - CAO
Who are the major shareholders of Corcept Therapeutics Inc?

Here are the top five shareholders of Corcept Therapeutics Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 12.6% (14.6m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.15% (11.7m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 7.72% (8.92m shares)
Ingalls & Snyder LLC (Asset Management) Investment Advisor/Hedge Fund
Percentage owned: 6.58% (7.60m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 5.59% (6.46m shares)
Similar to CORT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.